BridgeBio Pharma BBIO Reportable Segment — Income (Loss) from Equity Method Investments

Similar metrics at other companies

DKNGReportable Segment — Income (Loss) from Equity Method Investments

$45K+114%

JLLReportable Subsegments — Income Loss From Equity Method Investments

$700K+16.7%

NBIXReportable Segment — Unrealized gain (loss) on equity investments

$25.3M+183%

BWXTOperating Segments — Income Loss From Equity Method Investments

$7.59M+123%

BWXTAll Other Segments — Income Loss From Equity Method Investments

$0—

PEA

PEAKLifescience — Income Loss From Equity Method Investments

——

Questions, answered.

What is BridgeBio Pharma's reportable segment — income (loss) from equity method investments?

BridgeBio Pharma (BBIO) reported reportable segment — income (loss) from equity method investments of -$18.28M in Q1 2026.

How has BridgeBio Pharma's reportable segment — income (loss) from equity method investments changed year-over-year?

BridgeBio Pharma's reportable segment — income (loss) from equity method investments decreased by 17.5% year-over-year, from -$15.56M to -$18.28M.

What does reportable segment — income (loss) from equity method investments mean?

The company's portion of profits or losses from businesses where it holds a significant minority stake.

How do you interpret reportable segment — income (loss) from equity method investments?

Positive values indicate profitable performance of partner entities, while negative values reflect losses incurred by those investments.

How does reportable segment — income (loss) from equity method investments compare across companies?

Standard for pharmaceutical companies that utilize joint ventures or minority equity stakes to share R&D risks.